Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 21, Issue 22
15 November 2015
Issue Cover
All Issues
  • Cover Image

    Cover Image

    issue cover
    The cover shows ESR1 expression in MCF7 breast cancer cells as detected by in-cell Western blot analysis. Diminishing signal (left to right) denotes loss of ESR1 expression in response to treatment with selective estrogen receptor downregulators.  For details, see the article by Wardell and colleagues on page 5121 of this issue.
  • PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265

Highlights

Highlights of This Issue
View articletitled, Highlights of This Issue
Open the PDF for in another window

20th Anniversary Commentary

CCR 20th Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology
Axel Hoos; Jedd D. Wolchok; Rachel W. Humphrey; F. Stephen Hodi
View articletitled, <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology
Open the PDF for in another window
CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer
Niven Mehra; Zafeiris Zafeiriou; David Lorente; Leon W.M.M. Terstappen; Johann S. de Bono
View articletitled, <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer
Open the PDF for in another window

CCR Translations

Metabolic Imaging as a Biomarker of Early Radiation Response in Tumors
Stephen Y. Lai; C. David Fuller; Pratip K. Bhattacharya; Steven J. Frank
View articletitled, Metabolic Imaging as a Biomarker of Early Radiation Response in Tumors
Open the PDF for in another window
“Braking” the Cycle of Resistance in Endocrine Therapy for Breast Cancer
Angela DeMichele; Lewis A. Chodosh
View articletitled, “Braking” the Cycle of Resistance in Endocrine Therapy for Breast Cancer
Open the PDF for in another window

Molecular Pathways

Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor
Ana Sebio; Heinz-Josef Lenz
View articletitled, Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor
Open the PDF for in another window
Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer
Benjamin Purow
View articletitled, Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer
Open the PDF for in another window

CCR Focus

How Do Cancer Cells Die?
Susan E. Bates
View articletitled, How Do Cancer Cells Die?
Open the PDF for in another window
Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell!
Anthony Letai
View articletitled, Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell!
Open the PDF for in another window
BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis
Christopher J. Gibson; Matthew S. Davids
View articletitled, BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis
Open the PDF for in another window
Promises and Challenges of Smac Mimetics as Cancer Therapeutics
Simone Fulda
View articletitled, Promises and Challenges of Smac Mimetics as Cancer Therapeutics
Open the PDF for in another window
Autophagy, Metabolism, and Cancer
Eileen White; Janice M. Mehnert; Chang S. Chan
View articletitled, Autophagy, Metabolism, and Cancer
Open the PDF for in another window
How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Luis Martínez-Lostao; Alberto Anel; Julián Pardo
View articletitled, How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Open the PDF for in another window

Review

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Lesley Seymour; Susan Groshen; Gary L. Rosner; Daniel M. Sullivan; David R. Spriggs; Steven Reeves; Amy Gravell; S. Percy Ivy; Mark J. Ratain
View articletitled, Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Open the PDF for in another window

Cancer Therapy: Clinical

A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients
Yuna Guo; S. Ray Kenney; Linda Cook; Sarah F. Adams; Teresa Rutledge; Elsa Romero; Tudor I. Oprea; Larry A. Sklar; Edward Bedrick; Charles L. Wiggins; Huining Kang; Lesley Lomo; Carolyn Y. Muller; Angela Wandinger-Ness; Laurie G. Hudson
View articletitled, A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients
Supplementary data
Open the PDF for in another window

Personalized Medicine and Imaging

13C-MR Spectroscopic Imaging with Hyperpolarized [1-13C]pyruvate Detects Early Response to Radiotherapy in SCC Tumors and HT-29 Tumors
Keita Saito; Shingo Matsumoto; Yoichi Takakusagi; Masayuki Matsuo; H. Douglas Morris; Martin J. Lizak; Jeeva P. Munasinghe; Nallathamby Devasahayam; Sankaran Subramanian; James B. Mitchell; Murali C. Krishna
View articletitled, <sup>13</sup>C-MR Spectroscopic Imaging with Hyperpolarized [1-<sup>13</sup>C]pyruvate Detects Early Response to Radiotherapy in SCC Tumors and HT-29 Tumors
Open the PDF for in another window
Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Bryan P. Schneider; Lang Li; Milan Radovich; Fei Shen; Kathy D. Miller; David A. Flockhart; Guanglong Jiang; Gail Vance; Laura Gardner; Matteo Vatta; Shaochun Bai; Dongbing Lai; Daniel Koller; Fengmin Zhao; Anne O'Neill; Mary Lou Smith; Elda Railey; Carol White; Ann Partridge; Joseph Sparano; Nancy E. Davidson; Tatiana Foroud; George W. Sledge, Jr
View articletitled, Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Supplementary data
Open the PDF for in another window
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide
Peter H. O'Donnell; Sanja Karovic; Theodore G. Karrison; Linda Janisch; Matthew R. Levine; Pamela J. Harris; Blase N. Polite; Ezra E.W. Cohen; Gini F. Fleming; Mark J. Ratain; Michael L. Maitland
View articletitled, Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide
Supplementary data
Open the PDF for in another window

Cancer Therapy: Preclinical

Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
M. Emmy M. Dolman; Evon Poon; Marli E. Ebus; Ilona J.M. den Hartog; Carel J.M. van Noesel; Yann Jamin; Albert Hallsworth; Simon P. Robinson; Kevin Petrie; Rolf W. Sparidans; Robbert J. Kok; Rogier Versteeg; Huib N. Caron; Louis Chesler; Jan J. Molenaar
View articletitled, Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
Supplementary data
Open the PDF for in another window
Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer
Viviana De Rosa; Francesca Iommelli; Marcello Monti; Rosa Fonti; Giuseppina Votta; Maria Patrizia Stoppelli; Silvana Del Vecchio
View articletitled, Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer
Open the PDF for in another window
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Suzanne E. Wardell; Matthew J. Ellis; Holly M. Alley; Koleen Eisele; Todd VanArsdale; Stephen G. Dann; Kim T. Arndt; Tina Primeau; Elizabeth Griffin; Jieya Shao; Robert Crowder; Jin-Ping Lai; John D. Norris; Donald P. McDonnell; Shunqiang Li
View articletitled, Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplementary data
Open the PDF for in another window
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Robert M. Sharkey; William J. McBride; Thomas M. Cardillo; Serengulam V. Govindan; Yang Wang; Edmund A. Rossi; Chien-Hsing Chang; David M. Goldenberg
View articletitled, Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Supplementary data
Open the PDF for in another window
Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody–Drug Conjugate as a Therapeutic for Non–Small Cell Lung and Ovarian Cancers
Kedan Lin; Bonnee Rubinfeld; Crystal Zhang; Ron Firestein; Eric Harstad; Leslie Roth; Siao Ping Tsai; Melissa Schutten; Keyang Xu; Maria Hristopoulos; Paul Polakis
View articletitled, Preclinical Development of an Anti-NaPi2b (<em>SLC34A2</em>) Antibody–Drug Conjugate as a Therapeutic for Non–Small Cell Lung and Ovarian Cancers
Open the PDF for in another window
Author Choice
Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer
Anand Kamal Singh; Nishi Chandra; Sharmila A. Bapat
View articletitled, Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer
Supplementary data
Open the PDF for in another window

Biology of Human Tumors

Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome
Anna Caliò; Alberto Zamò; Maurilio Ponzoni; Maria Elisabetta Zanolin; Andrés J.M. Ferreri; Serena Pedron; Licia Montagna; Claudia Parolini; Vadim E. Fraifeld; Marina Wolfson; Hagai Yanai; Giovanni Pizzolo; Claudio Doglioni; Fabrizio Vinante; Marco Chilosi
View articletitled, Cellular Senescence Markers p16<sup>INK4a</sup> and p21<sup>CIP1/WAF</sup> Are Predictors of Hodgkin Lymphoma Outcome
Supplementary data
Open the PDF for in another window
TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation–Positive Non–Small Cell Lung Cancer
Rongrong Wei; Lan Cao; Hengying Pu; Hongwei Wang; Yonglan Zheng; Xiaomin Niu; Xiaoling Weng; Hong Zhang; Murray J. Favus; Lanjun Zhang; Weihua Jia; Yixin Zeng; Christopher I. Amos; Shun Lu; Hui-Yun Wang; Yun Liu; Wanqing Liu
View articletitled, <em>TERT</em> Polymorphism rs2736100-C Is Associated with EGFR Mutation–Positive Non–Small Cell Lung Cancer
Open the PDF for in another window

Correction

Correction: Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma
View articletitled, Correction: Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma
Open the PDF for in another window

Advertisement

Breaking
Federal Health Officials Told to Freeze Public Communications
FDA Approves Drugs for MCL, Colorectal and Breast Cancers
NCI, NIH Directors Stepping Down
View more recent articles
Latest News
Genome Editing Sheds Light on BRCA2 Mutations
Wildfires Spare Los Angeles Area Cancer Centers—For Now
Structural Variants Increase Risk of Pediatric Cancers
View more recent articles
Research Watch
AI Models Can Effectively Detect Ovarian Cancer from Ultrasound Images
Bile Acids Modulate T-cell Response and Function in Liver Cancer
The Zinc-Binding Cysteine Proteome Comprises Targetable Cancer Vulnerabilities
View more recent articles

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.

  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2025 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept